STOCKWATCH: Vertex's almost incomplete disclosure
This article was originally published in Scrip
That infamous letter from three members of the US House of Representatives to the CEO of Gilead Sciences (which we hold), questioning the price of Sovaldi (sofosbuvir) in the treatment of hepatitis C virus (HCV) infection, has come to be known as the catalyst that started the great biotech sell-off of 2014 (scripintelligence.com, 25 March 2014). The tempo of the debate on US drug pricing was further accelerated when the CEO of the largest pharmacy benefit manager, Express Scripts, warned that the price of Sovaldi was unsustainable and called for its clients to stop using it when competitor drugs gain approval.
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.